Microneedle patch as a new platform to effectively deliver inactivated polio vaccine and inactivated rotavirus vaccine

• Published in: npj vaccines 2022-02, Vol.7 (1), p.26-26, Article 26
• Main Authors: Moon, Sung-Sil, Richter-Roche, Marly, Resch, Theresa K., Wang, Yuhuan, Foytich, Kimberly R., Wang, Houping, Mainou, Bernardo A., Pewin, Winston, Lee, Jeongwoo, Henry, Sebastien, McAllister, Devin V., Jiang, Baoming
• Format: Article
• Language: English
• Subjects: 631/61/24/590; 692/699/255/2514; Biomedical and Life Sciences; Biomedicine; Drug delivery systems; Immunogenicity; Infectious Diseases; Medical Microbiology; Public Health; Rodents; Rotavirus; Vaccine; Vaccines; Virology; Viruses
• ISSN: 2059-0105; 2059-0105
• DOI: 10.1038/s41541-022-00443-7

We recently reported a lack of interference between inactivated rotavirus vaccine (IRV) and inactivated poliovirus vaccine (IPV) and their potential dose sparing when the two vaccines were administered intramuscularly either in combination or standalone in rats and guinea pigs. In the present study, we optimized the formulations of both vaccines and investigated the feasibility of manufacturing a combined IRV-IPV dissolving microneedle patch (dMNP), assessing its compatibility and immunogenicity in rats. Our results showed that IRV delivered by dMNP alone or in combination with IPV induced similar levels of RV-specific IgG and neutralizing antibody. Likewise, IPV delivered by dMNP alone or in combination with IRV induced comparable levels of neutralizing antibody of poliovirus types 1, 2, and 3. We further demonstrated high stability of IRV-dMNP at 5, 25, and 40 °C and IPV-dMNP at 5 and 25 °C, and found that three doses of IRV or IPV when co-administered at a quarter dose was as potent as a full target dose in inducing neutralizing antibodies against corresponding rotavirus or poliovirus. We conclude that IRV-IPV dMNP did not interfere with each other in triggering an immunologic response and were highly immunogenic in rats. Our findings support the further development of this innovative approach to deliver a novel combination vaccine against rotavirus and poliovirus in children throughout the world.